Back to top

Analyst Blog

Genetic products company, Affymetrix Inc. (AFFX - Analyst Report), inked a ‘Powered by Affymetrix’ (“PbA”) Program agreement with Korea-based biotechnology company, DNA Link Inc. Following the terms of the deal, DNA Link acquired a global license to use Affymetrix’s GeneChip System 3000Dx v.2 along with other microarray technologies to develop a forensic test for human identification.

The GCS 3000Dx v.2 from Affymetrix is a second-generation solution for DNA and RNA analysis. It has received the U.S. Food and Drug Administration (“FDA”) approval as well as the European CE Mark for in vitro diagnostic (“IVD”) uses. The system has also been cleared by the Korean FDA.

DNA Link intends to combine Affymetrix’s leading GeneChip technology with its cutting-edge forensic test, AccuID Chip, to develop innovative molecular diagnostic tests for personalized healthcare in the field of genomics.  

Earlier, in Aug 2012, Affymetrix had signed a PbA Program agreement with a Singapore-based molecular diagnostics company, PathGEN Dx Pte. Ltd. Apart from PathGEN Dx, the company shares its technology with Roche Diagnostics, a unit of Roche Holdings Ltd. (RHHBY - Analyst Report), and Pathwork Diagnostics.

Our Take

Affymetrix is a leading provider of microarray-based products and services to the global research community. Apart from Illumina Inc. (ILMN - Analyst Report), it is one of the two major providers of microarray technologies, primarily serving the field of genetic research.

The latest agreement is in accordance with Affymetrix’s strategy to expand its customer base through strategic alliances. Moreover, the company is pursuing a number of strategies (including acquisitions and expansion into new markets) aimed at expanding its top line.

The ‘Powered by Affymetrix’ Program is an initiative by Affymetrix, which allows other companies to gain access to its GeneChip technology in order to develop new microarray products and solutions. The collaboration with DNA Link marks Affymetrix’s first partnership venture in Korea. The agreement further allows Affymetrix’s other PbA partners to enter Korea’s personalized genomics market.  

However, research and development spending by Affymetrix’s customers have fallen considerably due to a weak macroeconomic environment coupled with stringent government actions including budget cuts.

The company currently carries a Zacks Rank #3 (Hold). Biotechnology company, Alkermes plc. (ALKS - Analyst Report), carrying a Zacks Rank #1 (Strong Buy), is expected to do well in the Medical-Biomed/Gene industry.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%